GeNeuro SA (GNRO.PA)
| Previous Close | 0.0772 |
| Open | 0.0848 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.0800 - 0.0848 |
| 52 Week Range | 0.0558 - 2.3500 |
| Volume | |
| Avg. Volume | 36,218 |
| Market Cap | 2.451M |
| Beta (5Y Monthly) | 0.37 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5900 |
| Earnings Date | Oct 21, 2024 - Oct 22, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Business WireGeNeuro SA Obtains the Opening of Debt-Restructuring Proceedings
GENEVA, September 30, 2024--Regulatory News: GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that the Geneva Court of First Instance has approved its application for a debt-restructuring moratorium dated July 15, 2024, aimed at restructuring its debts and finding solutions for the continuity of its activities in the interests of all stakeholders.
Business WireGeNeuro: New Data Presented at the ECTRIMS 2025 Congress in Copenhagen Shows That Temelimab Rescues the Neurodegenerative Effects of HERV-W in an MS Model
GENEVA, September 19, 2024--Regulatory News: GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company focused on addressing the factors driving the progression of neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today announced that new findings on the anti-neurodegenerative effect of Temelimab in an MS model were presented as a poster at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2024 Congress in Copenhagen, Den
